Coherus BioSciences expects to receive a US Food and Drug Administration decision on its CHS-1420 adalimumab biosimilar candidate in December this year, the firm has revealed, after the agency accepted for filing its biologics license application for the rival to Humira.
“If approved, Coherus plans to launch the adalimumab biosimilar in the US on or after 1 July 2023, per the...






